Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Gilead teams with Nurix for protein degradation
by Lisa M. Jarvis
June 22, 2019
| A version of this story appeared in
Volume 97, Issue 25
Gilead Sciences will pay Nurix Therapeutics $45 million up front to collaborate on targeted protein degradation therapies for cancer and other diseases. Whereas conventional small-molecule drugs block the function of a protein, Nurix’s compounds can break down the protein altogether. The biotech firm’s technology harnesses enzymes called E3 ligases that dictate when a protein gets broken down in the cell. Under the multiyear pact, Gilead can license drug candidates against five undisclosed protein targets.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X